Intellia Therapeutics

Intellia develops gene editing treatments for rare, serious diseases. Its therapies aim to help people with inherited conditions. The company uses gene editing to target the root cause of illness.

Gene Editing, Simplified: What Intellia Sells

• In Vivo Therapies: Gene editing treatments delivered directly into the body, targeting diseases like hereditary angioedema and transthyretin amyloidosis. (100% of revenue from collaborations; no product sales)
• Ex Vivo Therapies: Engineered cell therapies developed outside the body for blood cancers and autoimmune diseases. (No direct revenue yet)
• CRISPR/Cas9 Platform: Tools and technology for precise gene editing, licensed to partners. (Collaboration revenue only)
• Collaborative Programs: Joint development with partners for new gene therapies, mainly with Regeneron and Novartis. (Majority of collaboration revenue)

Growth Spurts and Strategic Moves

• Formed major collaborations with Regeneron (2016), Novartis (2014), and SparingVision (2021).
• Expanded pipeline to Phase 3 trials for two lead therapies by 2025.
• Signed new lease for expanded lab and office space in Cambridge in 2026.
• Reduced workforce and restructured operations in 2025 to focus on core programs.
• Entered new disease areas through partnerships with AvenCell and Kyverna in 2024-2025.

Why Intellia Catches the Eye

Intellia is the first to bring in vivo gene editing to late-stage trials. Its single-dose therapies aim for lasting effects with one treatment. The company’s broad partnerships and intellectual property support its position in gene editing.

Five Things You Need to Know

• Revenue was $67.7 million in 2025, up 16.9% from 2024.
• Net loss was $412.7 million in 2025, improving 20.5% from 2024.
• Cash and investments totaled $605.1 million at December 31, 2025.
• All revenue comes from collaborations; no product sales as of 2025.
• R&D expenses fell 17% in 2025 due to restructuring and portfolio focus.

Bottom Line

Intellia has evolved from early research to late-stage clinical trials. Its focus on gene editing and strategic partnerships shapes its future in biotechnology.